Vidac Pharma Reports Topline Results from Exploratory Phase 2b Study of VDA-1102 in Actinic Keratosis
Clinical and imaging data inform further development of Vidac’s investigational topical treatment. London, UK, 9 November 2026 – Vidac Pharma Holdings Plc. announces topline results from its randomized, double-blind, placebo-controlled Phase 2b study evaluating topical VDA-1102 in rapidly proliferating actinic keratosis (AK).

